NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12
News Sep 04, 2009
NOXXON Pharma AG has announced that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (KMU-Innovativ).
The grant was presented to NOXXON following the completion of a peer reviewed selection process. Under the initiative NOXXON will receive 1.2 million Euro (1.7 million US$) in funding for the impending phase I clinical development of its candidate Spiegelmer® NOX-A12.
The company develops NOX-A12 for use in autologous hematopoietic stem cell transplantation in patients suffering from non-Hodgkin’s lymphoma or multiple myeloma.
NOXXON’s Chief Executive Officer Frank Morich commented: “In awarding this competitive research grant to NOXXON, the BMBF acknowledges our tremendous progress in maturing Spiegelmer® compounds into therapeutic candidates for human use. The transition from pre-clinical studies to clinical trials is a critical junction in the development of an innovative compound. We are grateful to the BMBF for providing grant support at this crucial stage.”
Spiegelmers® (L-aptamers) are chemical entities based on synthetic mirror-image oligonucleotides. Due to their unique mirror image configuration Spiegelmers® are not metabolized and do not hybridize with native nucleic acids. Spiegelmers® also do not activate the innate immune response via Toll-like receptors and have shown an exceptionally favorable immunogenicity profile in pre-clinical testing.
The phase I clinical development of NOX-A12 will follow closely behind that of NOXXON’s lead candidate NOX-E36, which entered human testing in June of 2009.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Unraveling How Mesenchymal Stem Cells From Gum Tissue Accelerate Wound HealingNews
To assist with wound healing, mesenchymal stem cells from the gum tissue secrete extracellular vesicles that contain the anti-inflammatory signaling molecule IL-1RA.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018